Haemonetics Liabilities 2024

Haemonetics Aktienanalyse

What does Haemonetics do?

Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Haemonetics's Liabilities

Haemonetics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Haemonetics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Haemonetics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Haemonetics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Haemonetics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Haemonetics stock

What is the level of liabilities of Haemonetics this year?

Haemonetics has a debt balance of 1.24 B USD this year.

What were the liabilities of Haemonetics compared to the previous year?

The liabilities of Haemonetics have increased by 11.29% increased compared to the previous year.

What are the consequences of high debt for investors of Haemonetics?

High liabilities can pose a risk for investors of Haemonetics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Haemonetics?

Low liabilities mean that Haemonetics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Haemonetics affect the company?

An increase in liabilities of Haemonetics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Haemonetics affect the company?

A decrease in the liabilities of Haemonetics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Haemonetics?

Some factors that can influence the liabilities of Haemonetics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Haemonetics so important for investors?

The liabilities of Haemonetics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Haemonetics take to modify the liabilities?

To change its liabilities, Haemonetics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Haemonetics pay?

Over the past 12 months, Haemonetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Haemonetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Haemonetics?

The current dividend yield of Haemonetics is .

When does Haemonetics pay dividends?

Haemonetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Haemonetics?

Haemonetics paid dividends every year for the past 0 years.

What is the dividend of Haemonetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Haemonetics located?

Haemonetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Haemonetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Haemonetics from 8/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/10/2024.

When did Haemonetics pay the last dividend?

The last dividend was paid out on 8/10/2024.

What was the dividend of Haemonetics in the year 2023?

In the year 2023, Haemonetics distributed 0 USD as dividends.

In which currency does Haemonetics pay out the dividend?

The dividends of Haemonetics are distributed in USD.